Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud, +18

The Lancet Oncology

Interim AnalysisSurgical OncologyOncologyPembrolizumab Versus PlaceboImmunology +6

Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study

Luca Valerio, Anna C. Mavromanoli, Stefano Barco, +29

European Heart Journal

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park, +164

Annals of Oncology

Essential role of calcium in vascular endothelial growth factor A‐induced signaling: mechanism of the antiangiogenic effect of carboxyamidotriazole

Martin Faehling, Karl J. Föhr, Guido Fellbrich, +3

The FASEB Journal

Calcium SignalingCellular PhysiologyTumor BiologyTumor AngiogenesisInflammation +17

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Solange Peters, Jean-Louis Pujol, Urania Dafni, +112

Annals of Oncology

OncologyImmune Checkpoint InhibitorConsolidation NivolumabCancer TreatmentIpilimumab Versus Observation +4

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases

Anna‐Lena Volckmar, Jonas Leichsenring, Martina Kirchner, +26

International Journal of Cancer

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, +193

Journal of Clinical Oncology

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin, +179

Annals of Oncology

Nivolumab Versus DocetaxelMedicinePharmacologyAnti-cancer AgentPhase Iii Study +5

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

Martin Faehling, Christian Schumann, Petros Christopoulos, +9

Lung Cancer

Radiation MedicineMedicineReal-world DataCancer ManagementGerman Expanded-access Program +7

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

L. Paz-Ares, E O’Brien, M. Mauer, +17

Annals of Oncology

MedicineClinical TrialsAdjuvant ChemotherapyImmune Checkpoint InhibitorPharmacotherapy +7